Quick answer
How is PT-141 used in receptor assays? As a reference ligand for melanocortin receptors in two assay families: competition radioligand binding (IC50 converted to Ki with the Cheng-Prusoff relationship) and Gs-cAMP functional assays that give EC50 and Emax against a reference agonist. The vial is 10 mg lyophilized, formula C50H68N14O10, about 1025.2 g/mol. Subtype selectivity needs the same series run against each receptor. Use the calculator for volumes and check lots on the COA page. For laboratory research use only.
PT-141 (bremelanotide) is sold to laboratories as a reference ligand for the central melanocortin receptors, and the experiments that make use of it are the standard ones for any G protein-coupled receptor: competition binding with a radiolabeled ligand, and functional cAMP assays in cells that express one receptor subtype at a time. This guide is a methods-level walk through those two assay families as they apply to a cyclic melanocortin peptide: how the receptor family is organized, how to design a binding and a cAMP experiment, what controls matter, the formula-level arithmetic for concentration series, and where the data usually go wrong. It makes no statement about any use outside the laboratory.
The target family in two paragraphs
Melanocortin signaling is defined by five G protein-coupled receptors (MC1R to MC5R), peptide agonists derived from the proopiomelanocortin precursor, and the endogenous antagonists agouti and agouti-related protein; the system has been linked to pigmentation, adrenocortical steroidogenesis, energy homeostasis and other physiological functions (Cone, 2006). The first receptors in the family were cloned in the early 1990s: Mountjoy and colleagues reported murine and human MSH receptors and a human ACTH receptor that define a subfamily of G protein-coupled receptors (Mountjoy et al., 1992), and a fourth subtype was cloned and characterized soon after (Gantz et al., 1993).
All five subtypes couple to Gs and raise intracellular cAMP when activated by an agonist. That shared signaling logic is why a cAMP readout works across the family and why selectivity has to be established by running the same compound against each receptor separately. A peptide described as an "MC4R agonist" is usually an agonist with a preference, not an exclusive ligand.
What the PT-141 vial is
The PT-141 product page lists a 10 mg lyophilized powder in a sealed clear glass vial, purity ≥98% by HPLC and the molecular formula C50H68N14O10. The sequence is given as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH: a cyclic heptapeptide with a lactam bridge between the Asp and Lys side chains. The page states it is structurally derived from Melanotan II and shares the same lactam-bridged ring, differing at the C-terminus, where PT-141 ends in a free carboxylic acid instead of an amide. From the formula the average molar mass is about 1025.2 g/mol. Storage is stated as 2–8 °C, or −20 °C for long-term holding, protected from heat, moisture and light.
The relationship to the amide analog matters for literature searching. Early animal studies used the amide, usually abbreviated MT-II, for example in a rat study that used selective antagonists to separate brain and spinal sites of melanocortin receptor action (Wessells et al., 2003), and a later review summarized preclinical central nervous system studies of bremelanotide itself (Pfaus et al., 2007). A paper that says "MT-II" is not a paper about the free acid, and a methods section should say which compound the cited data refer to. The lineage is covered in PT-141 vs Melanotan II, the background is in PT-141 research overview, and a short orientation is in what is PT-141.
Experiment 1: competition radioligand binding
A binding experiment asks how well an unlabeled test ligand displaces a labeled one from the receptor. The usual design uses membranes or whole cells expressing a single melanocortin receptor subtype, a radiolabeled high-affinity agonist such as an iodinated NDP-α-MSH analog, and a concentration series of the test compound.
| Component | Typical choice | Why |
|---|---|---|
| Receptor source | Membranes from cells stably expressing one human subtype | Removes cross-talk from other subtypes; allows direct subtype comparison |
| Labeled ligand | Radioiodinated NDP-MSH-type agonist at a concentration at or below its Kd | Keeps the assay sensitive to displacement |
| Test ligand series | Half-log steps spanning at least four log units | Defines both plateaus of the curve |
| Non-specific binding | Excess unlabeled reference ligand | Sets the floor of the displacement curve |
| Separation | Filtration or scintillation proximity | Separates bound from free label |
| Replicates | Duplicates or triplicates per concentration; at least three independent days | Day-to-day variation usually exceeds well-to-well variation |
The raw output is an IC50, the concentration of test ligand that halves specific labeled binding. IC50 depends on the labeled ligand concentration, so it is converted to an inhibition constant using the Cheng-Prusoff relationship, which links the inhibition constant to the concentration of inhibitor causing 50 per cent inhibition (Cheng and Prusoff, 1973). In its common form Ki = IC50 / (1 + [L]/Kd), where [L] is the labeled ligand concentration and Kd its dissociation constant for the same receptor preparation. The conversion assumes competitive, reversible binding at equilibrium, so incubation time must be long enough to reach it, and the Kd must be measured in the same system, not borrowed from another laboratory.
Experiment 2: functional cAMP assays
Binding says nothing about efficacy, which is what an agonist assay measures. Cells expressing one receptor subtype are exposed to the ligand series and cAMP is quantified, typically with a homogeneous fluorescence or luminescence assay. The readout gives EC50 (potency) and Emax (maximal response) relative to a full agonist.
| Design element | Recommendation | Failure mode if ignored |
|---|---|---|
| Phosphodiesterase inhibitor | Include at a fixed concentration in every well | cAMP degrades during the incubation and curves shift between plates |
| Reference agonist | NDP-α-MSH or α-MSH on every plate, normalizing Emax to it | Plate-to-plate drift looks like compound differences |
| Forskolin control | One well set to define the cell's maximum cAMP capacity | A ceiling effect is mistaken for partial agonism |
| Parental cells | Untransfected cells run in parallel | Endogenous receptors give a signal that is read as receptor-specific |
| Receptor expression level | Record it or use a titration of receptor density | High expression inflates apparent efficacy; low expression hides it |
| Incubation time | Fixed and short enough to avoid desensitization | Time-dependent loss of response is read as lower efficacy |
For subtype selectivity, run the identical series against each of the five receptors in cells with matched expression where possible, and report potency ratios with confidence intervals, not a single number from one plate. A claim that a compound is "selective" without that dataset is a summary of a rumor.
Concentration-series arithmetic
The mathematics is the same as for any peptide and is easiest to audit in symbolic form. Stock concentration is C = m / V, with m the vial mass in mg and V the diluent volume in mL. Molar concentration follows from C divided by the molar mass, about 1025.2 g/mol for this compound, and a serial dilution with factor f gives concentrations C, C/f, C/f², and so on. For a half-log series, f is the square root of ten, about 3.16. The reconstitution calculator performs the volume and unit conversions, and the bench steps are in how to reconstitute a lyophilized peptide. No per-vial table is given here because a number computed for one diluent volume is easy to misapply to another.
Plan the series from the assay backward: choose the top concentration the assay tolerates, check that the vehicle fraction in the highest well does not by itself change the signal, and prepare dilutions in low-binding plastic. A small cyclic peptide adsorbs less readily than a lipidated one, but dilute solutions still lose material to surfaces over time, so serial dilutions should be made fresh and used within the experiment.
Controls and what each rules out
- Vehicle only. Establishes the basal signal and confirms the diluent does not activate the readout.
- Reference agonist. Confirms the cells respond and defines 100% response.
- Selective antagonist. A reference antagonist that shifts the test ligand's curve supports a receptor-mediated effect. In the rat work cited above, the antagonist SHU-9119 was used for this purpose in vivo (Wessells et al., 2003).
- Parental cells. Rules out signals from endogenous receptors.
- Inactive analog or scrambled peptide. A same-composition control that should not activate the receptor.
- Independent lot. Repeating a key experiment with a second lot protects against a lot-specific artifact.
Quality checks before the first plate
Peptide identity and purity feed directly into the numbers above. A potency value computed from the label mass assumes that all of the vial mass is peptide, while counterions and residual water mean the true net peptide content is lower, so reported EC50 values can be biased high. The practical response is to read the certificate of analysis (lot documents are collected on the COA page), note the HPLC purity and mass-confirmation data, and, for publication-grade potency work, quantify the stock by amino-acid analysis or UV absorbance with the tryptophan and other chromophores in the sequence. Details of reading a trace are in PT-141 purity testing. The purchasing side is in where to buy PT-141, and the regulatory background is addressed in the library separately.
Reporting checklist
- Name the compound exactly (free acid or amide) and give lot number and purity.
- State the receptor species and subtype, expression system and passage range.
- Give the labeled ligand, its concentration and its measured Kd.
- Report IC50 and Ki together with the equation used.
- Report EC50 and Emax relative to a named reference agonist, with n and the number of independent days.
- Describe the curve model and the software used for fitting.
- Describe stock preparation: diluent, volume, storage and freeze-thaw count.
The compound and its neighbors in the research catalog are listed at the research shop.
Frequently asked questions
What is PT-141 used for in the laboratory?
As a reference ligand for central melanocortin receptors, mainly in binding and cAMP functional assays on MC3R and MC4R.
How does PT-141 differ chemically from Melanotan II?
Per the product page, they share the same lactam-bridged ring. PT-141 ends in a free carboxylic acid at the C-terminus where Melanotan II ends in an amide.
What molar mass applies to PT-141?
About 1025.2 g/mol from the listed formula C50H68N14O10. Confirm against the certificate of analysis for the lot.
What does a competition binding assay measure?
How well an unlabeled test ligand displaces a labeled ligand from the receptor, giving an IC50 that is converted to an inhibition constant.
What is the Cheng-Prusoff relationship?
A relationship linking the inhibition constant to the concentration of inhibitor that causes 50 per cent inhibition. In common form Ki = IC50 / (1 + [L]/Kd).
Why use a phosphodiesterase inhibitor in cAMP assays?
It limits cAMP breakdown during the incubation, which makes curves more reproducible between plates.
How is receptor selectivity established?
By running the same concentration series against each melanocortin receptor subtype in cells with matched expression and reporting potency ratios with confidence intervals.
Why does receptor expression level matter?
High expression can inflate apparent efficacy and low expression can hide it, so it should be recorded or titrated.
Why not give a table of concentrations per vial?
Numbers computed for one diluent volume are easily misapplied. The page gives the formula, and the reconstitution calculator works from the actual inputs.
How should the vial be stored?
The product page states 2–8 °C, −20 °C for long-term holding, and protection from heat, moisture and light.
Research-use statement
Everything on this page is educational background for laboratory research use only. V8 Peptides products are sold as research materials, not for human or animal consumption, and nothing here describes a use outside the laboratory. Browse the research catalog, check lot documents on the COA page, or run volumes through the reconstitution calculator.
Related reading: PT-141 and the Melanocortin Receptors: Assay Guide, PT-141 Structure: Cyclic Lactam, Sequence and Mass, How PT-141 Activates Melanocortin Receptors.
References
- Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736-749. doi:10.1210/er.2006-0034
- Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257(5074):1248-1251. doi:10.1126/science.1325670
- Gantz I, Miwa H, Konda Y, et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem. 1993;268(20):15174-15179. doi:10.1016/S0021-9258(18)82452-8
- Yung-Chi C, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22(23):3099-3108. doi:10.1016/0006-2952(73)90196-2
- Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P, Vanderah TW. Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience. 2003;118(3):755-762. doi:10.1016/S0306-4522(02)00866-7
- Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007;4(Suppl 4):269-279. doi:10.1111/j.1743-6109.2007.00610.x
